期刊
EUROPEAN CHILD & ADOLESCENT PSYCHIATRY
卷 20, 期 1, 页码 17-37出版社
SPRINGER
DOI: 10.1007/s00787-010-0140-6
关键词
ADHD; HKS; Medication; Adverse; Guidelines; European; Children
资金
- Lilly
- Medice
- Novartis
- UCB
- Shire
- Medical Research Council [G9817803B] Funding Source: researchfish
The safety of ADHD medications is not fully known. Concerns have arisen about both a lack of contemporary-standard information about medications first licensed several decades ago, and signals of possible harm arising from more recently developed medications. These relate to both relatively minor adverse effects and extremely serious issues such as sudden cardiac death and suicidality. A guidelines group of the European Network for Hyperkinetic Disorders (EUNETHYDIS) has therefore reviewed the literature, recruited renowned clinical sub-specialists and consulted as a group to examine these concerns. Some of the effects examined appeared to be minimal in impact or difficult to distinguish from risk to untreated populations. However, several areas require further study to allow a more precise understanding of these risks.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据